This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Revance Therapeutics’s 8K filing here.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Recommended Stories
- Five stocks we like better than Revance Therapeutics
- The How And Why of Investing in Oil Stocks
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Following Congress Stock Trades
- Top Nuclear Stocks Thriving on Soaring Energy Demand
- How to Invest in Blue Chip Stocks
- Apple Earnings – When Really Good Just Isn’t Good Enough
